Q-omics provides the consensus-scored RPL23AP25 profile across patient tissues and cancer cell-line models. RPL23AP25 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RPL23AP25 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, RPL23AP25 RNA expression shows 13,711 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, KIRC, and UVM as cancer lineages where RPL23AP25 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL23AP25 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL23AP25 survival associations across molecular data types. RPL23AP25 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL23AP25 RNA expression–survival associations across cancer types. High RPL23AP25 expression shows unfavorable associations in MESO, UVM and KICH, but favorable associations in CESC, BLCA and SKCM. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify MESO as the clearest survival context for RPL23AP25 RNA expression.
This table summarizes RPL23AP25 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL23AP25. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL23AP25 shows lower tumor expression in KIRC, THCA, UCEC, KIRP and LUSC and higher tumor expression in CHOL. The KIRC box plot shows higher RPL23AP25 RNA expression in normal versus tumor tissue (log2 FC = −0.120, t-test p = .003).
This table shows molecular features associated with RPL23AP25 in patient tissues and cancer cell lines. In patient samples, RPL23AP25 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
